Correlation of Influenza B Haemagglutination Inhibiton, Single-Radial Haemolysis and Pseudotype-Based Microneutralisation Assays for Immunogenicity Testing of Seasonal Vaccines.

George W Carnell,Claudia M Trombetta,Nigel J Temperton,Emanuele Montomoli,Francesca Ferrara

doi:10.3390/vaccines9020100

George W Carnell, Claudia M Trombetta + Show 3 more

Open Access

https://doi.org/10.3390/vaccines9020100

Copy DOI

Abstract

Influenza B is responsible for a significant proportion of the global morbidity, mortality and economic loss caused by influenza-related disease. Two antigenically distinct lineages co-circulate worldwide, often resulting in mismatches in vaccine coverage when vaccine predictions fail. There are currently operational issues with gold standard serological assays for influenza B, such as lack of sensitivity and requirement for specific antigen treatment. This study encompasses the gold standard assays with the more recent Pseudotype-based Microneutralisation assay in order to study comparative serological outcomes. Haemagglutination Inhibition, Single Radial Haemolysis and Pseudotype-based Microneutralisation correlated strongly for strains in the Yamagata lineage; however, it correlated with neither gold standard assays for the Victoria lineage.

Highlights

Influenza is a respiratory syndrome caused by three of six genera in the Orthomyxoviridae family, influenza A, B and C
Influenza B viruses comprise two co-circulating, antigenically distinct lineages that diverged from their progenitor, strain B/Hong Kong/8/1973, into the “Yamagata-like” (B/Yamagata/16/1988 type) and “Victoria-like” (B/Victoria/2/1987 type) lineages [2]
The results presented in this study, while discordant in regards to B/Brisbane/60/2008 PV, still represent the first comprehensive study correlating Haemagglutination Inhibition (HI), Single Radial Haemolysis (SRH) and Pseudotype-based Microneutralisation assay (pMN) assays for influenza B serology

Summary

Introduction

Influenza is a respiratory syndrome caused by three of six genera in the Orthomyxoviridae family, influenza A, B and C. Influenza B viruses comprise two co-circulating, antigenically distinct lineages that diverged from their progenitor, strain B/Hong Kong/8/1973, into the “Yamagata-like” (B/Yamagata/16/1988 type) and “Victoria-like” (B/Victoria/2/1987 type) lineages [2]. This human virus causes a significant proportion (20–30%) of global morbidity associated with influenza virus disease due to its global distribution and unpredictable switches in the predominating lineage circulating [3,4,5]. The WHO vaccine recommendations include an up-to-date strain from both lineages for quadrivalent vaccines, but only one for trivalent vaccines. In the United States, multiple quadrivalent vaccines have been approved and are in use [9]

Methods

Results

Conclusion